Jennifer A. Woyach, MD

Jennifer A. Woyach, MD, spoke about why it’s important to use newer therapies instead of chemoimmunotherapy for patients with chronic lymphocytic leukemia.

Jennifer A. Woyach, MD, spoke about the results of a study conducted in elderly patients treated with an ibrutinib-containing regimen for chronic lymphocytic leukemia at 55 months of follow-up.

Jennifer A. Woyach, MD, spoke about the phase 3 AO41202 study, which investigated different ibrutinib regimens for elderly patients with chronic lymphocytic leukemia.

Jennifer A. Woyach, MD, spoke about which abstracts she’s most excited to see presented at the 2021 American Society of Hematology Annual Meeting.

The Ohio State University Comprehensive Cancer Center expert discussed the ongoing Alliance A041702 trial at the ASH Annual Meeting and Exposition.

Elimination of chemotherapy from our combination regimens should be a shared goal among researchers that will move us a step closer to more patient-friendly and scientifically driven therapies for CLL.